Paradigm ups Profound Medical PT to C$45


Paradigm Capital raised its price target for Profound Medical (TSX:PRN; NASDAQ:PROF) to C$45 from C$40 based on the company’s commercialization plan for TULSA-PRO. The stock closed at $12.70 on the TSX on Nov. 5.

Profound, which cross-listed on Nasdaq last week, is commercializing TULSA-PRO, a technology designed to provide customizable radiation-free ablation of prostate tissue while protecting surrounding anatomy. TULSA-PRO received 510(k) clearance from the FDA in August 2019.

In its report, Paradigm stated that, “Profound’s long-term value is clear, driven by TULSA-PRO’s ability to provide effective treatment with fewer adverse events in the treatment of prostate cancer and BPH.”

Paradigm writes that while Profound plans to commercialize TULSA-PRO via a traditional capital equipment purchase model, it also intends to offer a pay-per-use option that would provide facilities with a TULSA-PRO unit at no upfront cost, charging a fee for each procedure.

The report concludes that Profound’s, “Different payment models offer a chance for rapid uptake of this technology, and the pay-per-use model establishes a second significant source of recurring revenue alongside the revenue generated from disposable sales.” 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.